Bacteriology and antimicrobial susceptibility of gram-positive cocci isolated from pus specimens of orofacial odontogenic infections.
We recently reported the beta-lactamase production and antimicrobial susceptibility of anaerobic gram-negative rods isolated from pus specimens of 93 orofacial odontogenic infections. In this report, we determine the bacteriology and antimicrobial susceptibility of bacteria other than anaerobic gram-negative rods, mainly gram-positive cocci, isolated from the same specimens. Streptococcus constellatus and Peptostreptococcus micros were frequent isolates from all types of infection examined. Peptostreptococcus prevotii, Corynebacterium species, and Eubacterium species were recovered only from dentoalveolar infections, while Gemella morbillorum was found more frequently in periodontitis than in the other infections. beta-Lactamase-positive strains were detected only in staphylococci. Ampicillin, ampicillin/sulbactam, cefazolin, cefotaxime, imipenem, erythromycin, clindamycin and levofloxacin showed high susceptibility rates (> or = 77%) against viridans streptococci, Peptostreptococcus and Gemella. Minocycline showed a high MIC90 value against viridans streptococci (32 microg/ml), and metronidazole was effective against Peptostreptococcus and Gemella. These results provide useful information for the treatment of orofacial odontogenic infections.
Kuriyama
T
T
Department of Oral and Maxillofacial Surgery, Kanazawa University Graduate School of Medical Science, Ishikawa, Japan.
Karasawa
T
T
Nakagawa
K
K
Yamamoto
E
E
Nakamura
S
S
D000667:Ampicillin / Q000494:pharmacology; D000900:Anti-Bacterial Agents / Q000494:pharmacology; D000890:Anti-Infective Agents / Q000494:pharmacology; D002437:Cefazolin / Q000494:pharmacology; D002439:Cefotaxime / Q000494:pharmacology; D002511:Cephalosporins / Q000494:pharmacology; D002981:Clindamycin / Q000494:pharmacology; D003352:Corynebacterium / Q000145:classification / Q000187:drug effects; D024881:Drug Resistance, Bacterial; D004917:Erythromycin / Q000494:pharmacology; D005051:Eubacterium / Q000145:classification / Q000187:drug effects; D016908:Gram-Positive Bacterial Infections / Q000382:microbiology*; D006095:Gram-Positive Cocci / Q000145:classification* / Q000187:drug effects; D006801:Humans; D015378:Imipenem / Q000494:pharmacology; D064704:Levofloxacin; D015242:Ofloxacin / Q000494:pharmacology; D010406:Penicillins / Q000494:pharmacology; D010462:Peptostreptococcus / Q000145:classification / Q000187:drug effects; D010518:Periodontitis / Q000382:microbiology; D013210:Staphylococcus / Q000145:classification / Q000201:enzymology; D013291:Streptococcus / Q000145:classification / Q000187:drug effects; D013407:Sulbactam / Q000494:pharmacology; D013845:Thienamycins / Q000494:pharmacology; D014076:Tooth Diseases / Q000382:microbiology*; D001618:beta-Lactamases / Q000378:metabolism
D000900:Anti-Bacterial Agents; D000890:Anti-Infective Agents; D002511:Cephalosporins; D010406:Penicillins; D013845:Thienamycins; D002981:Clindamycin; D004917:Erythromycin; D064704:Levofloxacin; D015378:Imipenem; D000667:Ampicillin; D015242:Ofloxacin; D001618:beta-Lactamases; D002437:Cefazolin; D002439:Cefotaxime; D013407:Sulbactam